Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration

James D. Chalmers1, Stefano Aliberti2,3, Josje Altenburg4, Francesco Blasi5,6, Clare Clarke1, Sanjay H. Chotirmall7,8, Megan L. Crichton1, Raja Dhar9, Pieter Goeminne10, Charles Haworth11, Michael R. Loebinger12, Natalie Lorent13,14, Eva Polverino15, Felix C. Ringshausen16,17,18, Amelia Shoemark1,12, Michał Shteinberg19, Oriol Sibila20, Arietta Spinou21 and Tobias Welte16,17,18

1Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. 2Department of Biomedical Sciences, Humanitas University, Milan, Italy. 3IRCCS Humanitas Research Hospital, Rozzano, Italy. 4Department of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. 5Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 6Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy. 7Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. 8Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore, Singapore. 9Department of Pulmonology, C K Birla Group of Hospitals, Kolkata, India. 10Department of Respiratory Disease, AZ Nikolaas, Sint-Niklaas, Belgium. 11Cambridge Centre for Lung Infection, Royal Papworth Hospital and University of Cambridge, Cambridge, UK. 12Royal Brompton and Harefield Hospitals, and National Heart and Lung Institute, Imperial College London, London, UK. 13Department of Pneumology, University Hospitals Leuven, Leuven, Belgium. 14Faculty of Medicine, Katholieke Universiteit Leuven, Leuven, Belgium. 15Pneumology Dept, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Ciber de Enfermedades Respiratorias CIBERES, Barcelona, Spain. 16Department of Respiratory Medicine, Hannover Medical School (MHH), Hannover, Germany. 17Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATHE), German Center for Lung Research (DZL), Hannover, Germany. 18European Reference Network on Rare and Complex Respiratory Diseases (ERN-LUNG), Frankfurt, Germany. 19Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel. 20Hospital Clinic of Barcelona, University of Barcelona, CIBERES, IDIBAPS, Barcelona, Spain. 21Population Health Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK.

Corresponding author: James D. Chalmers (jchalmers@dundee.ac.uk)

EMBARC3 is a programme of clinical and translational research aiming to improve our understanding of bronchiectasis globally


This single-page version can be shared freely online.

Bronchiectasis is a major health problem that is increasing in prevalence and burden globally [1, 2]. The impact of bronchiectasis on patients and the healthcare system is exacerbated by the decades in which the disease was under-recognised, under-researched and poorly treated [3]. There remain no treatments licensed by regulatory authorities worldwide, and many of the treatments that are used in routine clinical practice lack robust evidence [4]. Therapeutic development in bronchiectasis is undermined by the lack of experimental models and a lack of fundamental understanding of the disease. This makes bronchiectasis less attractive for investment into new therapeutic research compared to other fields.